Logo image of CORT

CORCEPT THERAPEUTICS INC (CORT) Stock Fundamental Analysis

NASDAQ:CORT - Nasdaq - US2183521028 - Common Stock - Currency: USD

62.24  -2.36 (-3.65%)

After market: 63.5 +1.26 (+2.02%)

Fundamental Rating

7

Taking everything into account, CORT scores 7 out of 10 in our fundamental rating. CORT was compared to 197 industry peers in the Pharmaceuticals industry. CORT has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. CORT is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings could make CORT a good candidate for growth and quality investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

CORT had positive earnings in the past year.
In the past year CORT had a positive cash flow from operations.
CORT had positive earnings in each of the past 5 years.
CORT had a positive operating cash flow in each of the past 5 years.
CORT Yearly Net Income VS EBIT VS OCF VS FCFCORT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

1.2 Ratios

CORT has a Return On Assets of 16.80%. This is amongst the best in the industry. CORT outperforms 97.46% of its industry peers.
Looking at the Return On Equity, with a value of 20.78%, CORT belongs to the top of the industry, outperforming 93.40% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 16.89%, CORT belongs to the top of the industry, outperforming 92.89% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for CORT is significantly below the industry average of 40.40%.
Industry RankSector Rank
ROA 16.8%
ROE 20.78%
ROIC 16.89%
ROA(3y)17.09%
ROA(5y)19.27%
ROE(3y)20.64%
ROE(5y)22.43%
ROIC(3y)17.94%
ROIC(5y)20.7%
CORT Yearly ROA, ROE, ROICCORT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

1.3 Margins

The Profit Margin of CORT (20.92%) is better than 93.91% of its industry peers.
In the last couple of years the Profit Margin of CORT has declined.
The Operating Margin of CORT (20.29%) is better than 86.29% of its industry peers.
CORT's Operating Margin has declined in the last couple of years.
CORT's Gross Margin of 98.39% is amongst the best of the industry. CORT outperforms 97.97% of its industry peers.
CORT's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 20.29%
PM (TTM) 20.92%
GM 98.39%
OM growth 3Y-15.83%
OM growth 5Y-11.04%
PM growth 3Y-12.04%
PM growth 5Y-7.41%
GM growth 3Y-0.06%
GM growth 5Y0.04%
CORT Yearly Profit, Operating, Gross MarginsCORT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so CORT is creating value.
CORT has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CORT has been reduced compared to 5 years ago.
CORT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CORT Yearly Shares OutstandingCORT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
CORT Yearly Total Debt VS Total AssetsCORT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 27.19 indicates that CORT is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 27.19, CORT belongs to the top of the industry, outperforming 94.92% of the companies in the same industry.
CORT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 27.19
ROIC/WACC1.75
WACC9.68%
CORT Yearly LT Debt VS Equity VS FCFCORT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.3 Liquidity

CORT has a Current Ratio of 3.35. This indicates that CORT is financially healthy and has no problem in meeting its short term obligations.
CORT's Current ratio of 3.35 is in line compared to the rest of the industry. CORT outperforms 56.85% of its industry peers.
CORT has a Quick Ratio of 3.26. This indicates that CORT is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.26, CORT perfoms like the industry average, outperforming 58.88% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.35
Quick Ratio 3.26
CORT Yearly Current Assets VS Current LiabilitesCORT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

9

3. Growth

3.1 Past

CORT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.53%, which is quite impressive.
CORT shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 9.71% yearly.
CORT shows a strong growth in Revenue. In the last year, the Revenue has grown by 39.93%.
The Revenue has been growing by 17.11% on average over the past years. This is quite good.
EPS 1Y (TTM)30.53%
EPS 3Y11.69%
EPS 5Y9.71%
EPS Q2Q%-7.14%
Revenue 1Y (TTM)39.93%
Revenue growth 3Y22.64%
Revenue growth 5Y17.11%
Sales Q2Q%34.33%

3.2 Future

The Earnings Per Share is expected to grow by 54.37% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 29.15% on average over the next years. This is a very strong growth
EPS Next Y57.11%
EPS Next 2Y70.7%
EPS Next 3Y67.86%
EPS Next 5Y54.37%
Revenue Next Year30.71%
Revenue Next 2Y31.35%
Revenue Next 3Y32.81%
Revenue Next 5Y29.15%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CORT Yearly Revenue VS EstimatesCORT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B
CORT Yearly EPS VS EstimatesCORT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 10 15

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 50.19, which means the current valuation is very expensive for CORT.
Based on the Price/Earnings ratio, CORT is valued a bit cheaper than 79.70% of the companies in the same industry.
When comparing the Price/Earnings ratio of CORT to the average of the S&P500 Index (28.29), we can say CORT is valued expensively.
With a Price/Forward Earnings ratio of 31.95, CORT can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, CORT is valued a bit cheaper than 78.68% of the companies in the same industry.
CORT's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 21.08.
Industry RankSector Rank
PE 50.19
Fwd PE 31.95
CORT Price Earnings VS Forward Price EarningsCORT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CORT indicates a somewhat cheap valuation: CORT is cheaper than 77.67% of the companies listed in the same industry.
79.19% of the companies in the same industry are more expensive than CORT, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 33.52
EV/EBITDA 43
CORT Per share dataCORT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CORT has a very decent profitability rating, which may justify a higher PE ratio.
CORT's earnings are expected to grow with 67.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.88
PEG (5Y)5.17
EPS Next 2Y70.7%
EPS Next 3Y67.86%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CORT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CORCEPT THERAPEUTICS INC

NASDAQ:CORT (4/17/2025, 8:10:38 PM)

After market: 63.5 +1.26 (+2.02%)

62.24

-2.36 (-3.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26 2025-02-26/amc
Earnings (Next)04-30 2025-04-30/amc
Inst Owners82.09%
Inst Owner Change-0.01%
Ins Owners6.52%
Ins Owner Change0.39%
Market Cap6.57B
Analysts82
Price Target145.35 (133.53%)
Short Float %17.23%
Short Ratio15.57
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.17%
Min EPS beat(2)-40.2%
Max EPS beat(2)42.54%
EPS beat(4)3
Avg EPS beat(4)12.54%
Min EPS beat(4)-40.2%
Max EPS beat(4)42.54%
EPS beat(8)6
Avg EPS beat(8)14.58%
EPS beat(12)8
Avg EPS beat(12)7.58%
EPS beat(16)11
Avg EPS beat(16)8.96%
Revenue beat(2)1
Avg Revenue beat(2)-3.09%
Min Revenue beat(2)-10.25%
Max Revenue beat(2)4.07%
Revenue beat(4)3
Avg Revenue beat(4)-0.2%
Min Revenue beat(4)-10.25%
Max Revenue beat(4)4.07%
Revenue beat(8)6
Avg Revenue beat(8)0.89%
Revenue beat(12)7
Avg Revenue beat(12)-0.9%
Revenue beat(16)8
Avg Revenue beat(16)-1.83%
PT rev (1m)42.86%
PT rev (3m)90.25%
EPS NQ rev (1m)-5%
EPS NQ rev (3m)-62.75%
EPS NY rev (1m)-9.37%
EPS NY rev (3m)9.06%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.35%
Revenue NY rev (1m)0%
Revenue NY rev (3m)11.76%
Valuation
Industry RankSector Rank
PE 50.19
Fwd PE 31.95
P/S 9.73
P/FCF 33.52
P/OCF 33.15
P/B 9.66
P/tB 9.66
EV/EBITDA 43
EPS(TTM)1.24
EY1.99%
EPS(NY)1.95
Fwd EY3.13%
FCF(TTM)1.86
FCFY2.98%
OCF(TTM)1.88
OCFY3.02%
SpS6.4
BVpS6.44
TBVpS6.44
PEG (NY)0.88
PEG (5Y)5.17
Profitability
Industry RankSector Rank
ROA 16.8%
ROE 20.78%
ROCE 19.57%
ROIC 16.89%
ROICexc 37.58%
ROICexgc 37.58%
OM 20.29%
PM (TTM) 20.92%
GM 98.39%
FCFM 29.02%
ROA(3y)17.09%
ROA(5y)19.27%
ROE(3y)20.64%
ROE(5y)22.43%
ROIC(3y)17.94%
ROIC(5y)20.7%
ROICexc(3y)74.13%
ROICexc(5y)85.06%
ROICexgc(3y)74.13%
ROICexgc(5y)85.06%
ROCE(3y)20.79%
ROCE(5y)23.98%
ROICexcg growth 3Y-18.86%
ROICexcg growth 5Y-17.58%
ROICexc growth 3Y-18.86%
ROICexc growth 5Y-17.58%
OM growth 3Y-15.83%
OM growth 5Y-11.04%
PM growth 3Y-12.04%
PM growth 5Y-7.41%
GM growth 3Y-0.06%
GM growth 5Y0.04%
F-Score6
Asset Turnover0.8
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 273.21%
Cap/Sales 0.32%
Interest Coverage 250
Cash Conversion 143.79%
Profit Quality 138.73%
Current Ratio 3.35
Quick Ratio 3.26
Altman-Z 27.19
F-Score6
WACC9.68%
ROIC/WACC1.75
Cap/Depr(3y)112.18%
Cap/Depr(5y)124.4%
Cap/Sales(3y)0.15%
Cap/Sales(5y)0.19%
Profit Quality(3y)125.51%
Profit Quality(5y)133.52%
High Growth Momentum
Growth
EPS 1Y (TTM)30.53%
EPS 3Y11.69%
EPS 5Y9.71%
EPS Q2Q%-7.14%
EPS Next Y57.11%
EPS Next 2Y70.7%
EPS Next 3Y67.86%
EPS Next 5Y54.37%
Revenue 1Y (TTM)39.93%
Revenue growth 3Y22.64%
Revenue growth 5Y17.11%
Sales Q2Q%34.33%
Revenue Next Year30.71%
Revenue Next 2Y31.35%
Revenue Next 3Y32.81%
Revenue Next 5Y29.15%
EBIT growth 1Y27.55%
EBIT growth 3Y3.23%
EBIT growth 5Y4.18%
EBIT Next Year9.57%
EBIT Next 3Y47.28%
EBIT Next 5Y19.15%
FCF growth 1Y54.37%
FCF growth 3Y5.38%
FCF growth 5Y7.73%
OCF growth 1Y55.91%
OCF growth 3Y5.66%
OCF growth 5Y7.79%